Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

Citation
Di. Daikh et D. Wofsy, Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide, J IMMUNOL, 166(5), 2001, pp. 2913-2916
Citations number
30
Categorie Soggetti
Immunology
Journal title
JOURNAL OF IMMUNOLOGY
ISSN journal
00221767 → ACNP
Volume
166
Issue
5
Year of publication
2001
Pages
2913 - 2916
Database
ISI
SICI code
0022-1767(20010301)166:5<2913:CEROML>2.0.ZU;2-X
Abstract
Cyclophosphamide (CTS) prevents progression of nephritis and prolongs survi val in (NZB x NZW)F-1 (B/W) mice and is used to treat humans with lupus nep hritis, To compare the efficacy of CTLA4Ig with CTS and determine whether t here is an incremental benefit to combining CTLA4Ig with CTX, we treated B/ W mice with CTS, CTLA4Ig, or both agents. In mice with mild renal disease, treatment delayed the onset of proteinuria and prolonged survival in all gr oups, In mice with advanced renal disease, treatment with both agents reduc ed proteinuria in 71% of mice? whereas mice treated with either agent alone had no such improvement. Survival was also markedly improved among mice tr eated with both agents. Thus, combination treatment with CTX and CTLA4Ig is more effective than either agent alone in reducing renal disease and prolo nging survival of B/W mice with advanced nephritis, This striking reversal of proteinuria is unprecedented in animal models of SLE.